RecruitingPhase 2NCT07441642
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
A Randomized, Double Masked, Placebo-controlled, Multicenter, Dose-range Finding Study to Assess the Efficacy and Safety of FWY003 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
Sponsor
Novartis Pharmaceuticals
Enrollment
272 participants
Start Date
Mar 9, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Eligibility
Min Age: 50 Years
Inclusion Criteria6
- Male or female participants ≥ 50 years of age.
- A diagnosis of GA secondary to AMD in at least one eye (study eye). If both eyes qualify, then the eye with the better BCVA would be assigned as study eye.
- Total GA area must be ≥2.5 and ≤17.5 mm2 (1 and 7 disk areas (DA), respectively)
- If GA lesion is multifocal, then the total lesion area must be between 2.5-17.5 mm2 and at least one lesion should have an area of at least 1.25 mm2
- Entire GA lesion must be visualized on the macula centered image and not contiguous with peripapillary atrophy
- ETDRS BCVA ≥ 35 letters (20/200) in the study eye.
Exclusion Criteria5
- A history of, or current evidence of, choroidal neovascularization (exudative MNV) in either eye, as determined by the central reading center on multimodal imaging at screening.
- Previous cell or gene therapy in either eye.
- Macular atrophy in either eye due to a cause other than AMD, such as Stargardt disease, cone rod dystrophy, toxic maculopathies, etc.
- Intraocular surgery, including cataract and vitreoretinal surgery, in the study eye within 3 months prior to Baseline.
- Presence of significant media opacity, eye movement disorder (nystagmus), severe ptosis, extraocular motility restriction or head tremor, which in the opinion of the investigator, would prevent adequate fundus visualization or interfere with retinal imaging data quality.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGFWY003
FWY003 arm participants will receive a specific dose of FWY003
DRUGPlacebo
Placebo arm participants will receive placebo
Locations(51)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07441642
Related Trials
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
NCT0714413713 locations
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
NCT0721539078 locations
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
NCT073922555 locations
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT0699026927 locations
Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy
NCT075319275 locations